Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2020 Sep;24(47):1–86. doi: 10.3310/hta24470

Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.

Richard Gilson, Diarmuid Nugent, Kate Bennett, Caroline J Doré, Macey L Murray, Jade Meadows, Lewis J Haddow, Charles Lacey, Frank Sandmann, Mark Jit, Kate Soldan, Michelle Tetlow, Emilia Caverly, Mayura Nathan, Andrew J Copas
PMCID: PMC7548868  PMID: 32975189

Abstract

BACKGROUND

The comparative efficacy, and cost-effectiveness, of imiquimod or podophyllotoxin cream, either alone or in combination with the quadrivalent HPV vaccine (Gardasil®, Merck Sharp & Dohme Corp., Merck & Co., Inc., Whitehouse Station, NJ, USA) in the treatment and prevention of recurrence of anogenital warts is not known.

OBJECTIVE

The objective was to compare the efficacy of imiquimod and podophyllotoxin creams to treat anogenital warts and to assess whether or not the addition of quadrivalent human papillomavirus vaccine increases wart clearance or prevention of recurrence.

DESIGN

A randomised, controlled, multicentre, partially blinded factorial trial. Participants were randomised equally to four groups, combining either topical treatment with quadrivalent human papillomavirus vaccine or placebo. Randomisation was stratified by gender, a history of previous warts and human immunodeficiency virus status. There was an accompanying economic evaluation, conducted from the provider perspective over the trial duration.

SETTING

The setting was 22 sexual health clinics in England and Wales.

PARTICIPANTS

Participants were patients with a first or repeat episode of anogenital warts who had not been treated in the previous 3 months and had not previously received quadrivalent human papillomavirus vaccine.

INTERVENTIONS

Participants were randomised to 5% imiquimod cream (Aldara®; Meda Pharmaceuticals, Takeley, UK) for up to 16 weeks or 0.15% podophyllotoxin cream (Warticon®; GlaxoSmithKlein plc, Brentford, UK) for 4 weeks, which was extended to up to 16 weeks if warts persisted. Participants were simultaneously randomised to quadrivalent human papillomavirus vaccine (Gardasil) or saline control at 0, 8 and 24 weeks. Cryotherapy was permitted after week 4 at the discretion of the investigator.

MAIN OUTCOME MEASURES

The main outcome measures were a combined primary outcome of wart clearance at week 16 and remaining wart free at week 48. Efficacy analysis was by logistic regression with multiple imputation for missing follow-up values; economic evaluation considered the costs per quality-adjusted life-year.

RESULTS

A total of 503 participants were enrolled and attended at least one follow-up visit. The mean age was 31 years, 66% of participants were male (24% of males were men who have sex with men), 50% had a previous history of warts and 2% were living with human immunodeficiency virus. For the primary outcome, the adjusted odds ratio for imiquimod cream versus podophyllotoxin cream was 0.81 (95% confidence interval 0.54 to 1.23), and for quadrivalent human papillomavirus vaccine versus placebo, the adjusted odds ratio was 1.46 (95% confidence interval 0.97 to 2.20). For the components of the primary outcome, the adjusted odds ratio for wart free at week 16 for imiquimod versus podophyllotoxin was 0.77 (95% confidence interval 0.52 to 1.14) and for quadrivalent human papillomavirus vaccine versus placebo was 1.30 (95% confidence interval 0.89 to 1.91). The adjusted odds ratio for remaining wart free at 48 weeks (in those who were wart free at week 16) for imiquimod versus podophyllotoxin was 0.98 (95% confidence interval 0.54 to 1.78) and for quadrivalent human papillomavirus vaccine versus placebo was 1.39 (95% confidence interval 0.73 to 2.63). Podophyllotoxin plus quadrivalent human papillomavirus vaccine had inconclusive cost-effectiveness compared with podophyllotoxin alone.

LIMITATIONS

Hepatitis A vaccine as control was replaced by a saline placebo in a non-identical syringe, administered by someone outside the research team, for logistical reasons. Sample size was reduced from 1000 to 500 because of slow recruitment and other delays.

CONCLUSIONS

A benefit of the vaccine was not demonstrated in this trial. The odds of clearance at week 16 and remaining clear at week 48 were 46% higher with vaccine, and consistent effects were seen for both wart clearance and recurrence separately, but these differences were not statistically significant. Imiquimod and podophyllotoxin creams had similar efficacy for wart clearance, but with a wide confidence interval. The trial results do not support earlier evidence of a lower recurrence with use of imiquimod than with use of podophyllotoxin. Podophyllotoxin without quadrivalent human papillomavirus vaccine is the most cost-effective strategy at the current vaccine list price. A further larger trial is needed to definitively investigate the effect of the vaccine; studies of the immune response in vaccine recipients are needed to investigate the mechanism of action.

TRIAL REGISTRATION

Current Controlled Trials. Current Controlled Trials ISRCTN32729817 and EudraCT 2013-002951-14.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 47. See the NIHR Journals Library website for further project information.

Plain language summary

The HIPvac [Human papillomavirus infection: a randomised controlled trial of Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts] trial compared two commonly used creams to treat genital warts: 0.15% podophyllotoxin cream (Warticon®; GlaxoSmithKlein plc, Brentford, UK) and 5% imiquimod cream (Aldara®; Meda Pharmaceuticals, Takeley, UK). It also investigated whether or not a vaccine used to prevent human papillomavirus infection, quadrivalent human papillomavirus vaccine (Gardasil®, Merck Sharp & Dohme Corp., Merck & Co., Inc., Whitehouse Station, NJ, USA), could help treat warts or prevent them from coming back in patients whose warts had been cleared. The HIPvac trial was a randomised controlled trial involving 503 patients with warts attending sexual health clinics in England and Wales. The creams and the vaccine were well tolerated; there was some soreness where the cream was applied, but no unexpected side effects. When deciding which treatment was better, we looked at whether or not the warts had cleared by 16 weeks after starting treatment and, if cleared, whether or not they returned by 48 weeks. We compared the creams against each other, and the addition of vaccine against no vaccine (a placebo injection). Patients were allowed to have cryotherapy (freezing treatment) as well, if the investigator advised this. We also calculated the value for money of each type of treatment. The two creams were very similar in how well they worked to clear the warts. One difference was that podophyllotoxin cream worked slightly quicker. The number of patients given cryotherapy was about the same for both types of cream. We had expected that recurrence of warts after treatment with imiquimod cream might be less than after treatment with podophyllotoxin cream, but, in fact, the two creams were similar. Quadrivalent human papillomavirus vaccine did not improve clearance of warts or reduce the chance of recurrence, but the result remains inconclusive. If we had been able to recuit 1000 participants as originally planned, we might have been able to be more certain about whether there was any benefit of vaccination. Further research would be needed to investigate any possible effect. The two creams offered similar value for money in treating warts. Giving patients the vaccine in addition to the cream is not good value for money at its current list price, given the uncertainty about the benefit it offers.

Full text of this article can be found in Bookshelf.

References

  1. Ball SL, Winder DM, Vaughan K, Hanna N, Levy J, Sterling JC, et al. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol 2011;83:1345–50. https://doi.org/10.1002/jmv.22111 doi: 10.1002/jmv.22111. [DOI] [PubMed]
  2. Public Health England (PHE). Sexually Transmitted Infections (STIs): Annual Data Tables. Table 1: STI Diagnoses and Rates in England by Gender, 2009 to 2018. London: PHE; 2019. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/805903/2018_Table_1_STI_diagnoses_and_rates_in_England_by_gender.ods (accessed 26 October 2018).
  3. Desai S, Wetten S, Woodhall SC, Peters L, Hughes G, Soldan K. Genital warts and cost of care in England. Sex Transm Infect 2011;87:464–8. https://doi.org/10.1136/sti.2010.048421 doi: 10.1136/sti.2010.048421. [DOI] [PMC free article] [PubMed]
  4. British Association for Sexual Health and HIV (BASHH). UK National Guidelines on the Management of Anogenital Warts 2015. URL: www.bashh.org/documents/UK%20national%20guideline%20on%20Warts%202015%20FINAL.pdf (accessed 4 February 2019).
  5. Lacey CJ, Woodhall SC, Wikstrom A, Ross J. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2013;27:e263–70. https://doi.org/10.1111/j.1468-3083.2012.04493.x doi: 10.1111/j.1468-3083.2012.04493.x. [DOI] [PubMed]
  6. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines, 2015. URL: www.cdc.gov/std/tg2015/default.htm (accessed 4 February 2019).
  7. Edwards A, Atma-Ram A, Thin RN. Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts. Genitourin Med 1988;64:263–5. https://doi.org/10.1136/sti.64.4.263 doi: 10.1136/sti.64.4.263. [DOI] [PMC free article] [PubMed]
  8. Beutner KR, Conant MA, Friedman-Kien AE, Illeman M, Artman NN, Thisted RA, King DH. Patient-applied podofilox for treatment of genital warts. Lancet 1989;1:831–4. https://doi.org/10.1016/S0140-6736(89)92282-4 doi: 10.1016/S0140-6736(89)92282-4. [DOI] [PubMed]
  9. Mazurkiewicz W, Jablońska S. Clinical efficacy of Condyline (0.5% podophyllotoxin) solution and cream versus podophyllin in the treatment of external condylomata acuminata. J Dermatolog Treat 1990;1:123–5. https://doi.org/10.3109/09546639009086712 doi: 10.3109/09546639009086712. [DOI]
  10. Kirby P, Dunne A, King DH, Corey L. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990;88:465–9. https://doi.org/10.1016/0002-9343(90)90424-C doi: 10.1016/0002-9343(90)90424-C. [DOI] [PubMed]
  11. von Krogh G, Szpak E, Andersson M, Bergelin I. Self-treatment using 0.25%–0.50% podophyllotoxin-ethanol solutions against penile condylomata acuminata: a placebo-controlled comparative study. Genitourin Med 1994;70:105–9. https://doi.org/10.1136/sti.70.2.105 doi: 10.1136/sti.70.2.105. [DOI] [PMC free article] [PubMed]
  12. Strand A, Brinkeborn RM, Siboulet A. Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution. Genitourin Med 1995;71:387–90. https://doi.org/10.1136/sti.71.6.387 doi: 10.1136/sti.71.6.387. [DOI] [PMC free article] [PubMed]
  13. Claesson U, Lassus A, Happonen H, Hogström L, Siboulet A. Topical treatment of venereal warts: a comparative open study of podophyllotoxin cream versus solution. Int J STD AIDS 1996;7:429–34. https://doi.org/10.1258/0956462961918400 doi: 10.1258/0956462961918400. [DOI] [PubMed]
  14. Lacey CJ, Goodall RL, Tennvall GR, Maw R, Kinghorn GR, Fisk PG, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003;79:270–5. https://doi.org/10.1136/sti.79.4.270 doi: 10.1136/sti.79.4.270. [DOI] [PMC free article] [PubMed]
  15. Komericki P, Akkilic-Materna M, Strimitzer T, Aberer W. Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts. Sex Transm Dis 2011;38:216–18. https://doi.org/10.1097/OLQ.0b013e3181f68ebb doi: 10.1097/OLQ.0b013e3181f68ebb. [DOI] [PubMed]
  16. Werner RN, Westfechtel L, Dressler C, Nast A. Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sex Transm Infect 2017;93:155–61. https://doi.org/10.1136/sextrans-2016-052768 doi: 10.1136/sextrans-2016-052768. [DOI] [PubMed]
  17. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis 2001;1:3. https://doi.org/10.1186/1471-2334-1-3 doi: 10.1186/1471-2334-1-3. [DOI] [PMC free article] [PubMed]
  18. Arany I, Tyring SK, Stanley MA, Tomai MA, Miller RL, Smith MH, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 1999;43:55–63. https://doi.org/10.1016/S0166-3542(99)00033-9 doi: 10.1016/S0166-3542(99)00033-9. [DOI] [PubMed]
  19. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230–9. https://doi.org/10.1016/S0190-9622(98)70243-9 doi: 10.1016/S0190-9622(98)70243-9. [DOI] [PubMed]
  20. Beutner KR, Tyring SK, Trofatter KF, Douglas JM, Spruance S, Owens ML, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998;42:789–94. https://doi.org/10.1128/AAC.42.4.789 doi: 10.1128/AAC.42.4.789. [DOI] [PMC free article] [PubMed]
  21. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998;134:25–30. https://doi.org/10.1001/archderm.134.1.25 doi: 10.1001/archderm.134.1.25. [DOI] [PubMed]
  22. Fife KH, Ferenczy A, Douglas JM, Brown DR, Smith M, Owens ML, HPV Study Group. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex Transm Dis 2001;28:226–31. https://doi.org/10.1097/00007435-200104000-00007 doi: 10.1097/00007435-200104000-00007. [DOI] [PubMed]
  23. Arican O, Guneri F, Bilgic K, Karaoglu A. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol 2004;31:627–31. https://doi.org/10.1111/j.1346-8138.2004.tb00568.x doi: 10.1111/j.1346-8138.2004.tb00568.x. [DOI] [PubMed]
  24. Garland SM, Waddell R, Mindel A, Denham IM, McCloskey JC. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS 2006;17:448–52. https://doi.org/10.1258/095646206777689161 doi: 10.1258/095646206777689161. [DOI] [PubMed]
  25. Schöfer H, Van Ophoven A, Henke U, Lenz T, Eul A. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur J Dermatol 2006;16:642–8. [PubMed]
  26. Grillo-Ardila CF, Angel-Müller E, Salazar-Díaz LC, Gaitán HG, Ruiz-Parra AI, Lethaby A. Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database Syst Rev 2014;11:CD010389. https://doi.org/10.1002/14651858.CD010389.pub2 doi: 10.1002/14651858.CD010389.pub2. [DOI] [PMC free article] [PubMed]
  27. Venugopal SS, Murrell DF. Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man. Arch Dermatol 2010;146:475–7. https://doi.org/10.1001/archdermatol.2010.71 doi: 10.1001/archdermatol.2010.71. [DOI] [PubMed]
  28. Lee HJ, Kim JK, Kim DH, Yoon MS. Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18). J Am Acad Dermatol 2011;64:e130–2. https://doi.org/10.1016/j.jaad.2010.12.032 doi: 10.1016/j.jaad.2010.12.032. [DOI] [PubMed]
  29. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009;5:696–704. https://doi.org/10.4161/hv.5.10.9515 doi: 10.4161/hv.5.10.9515. [DOI] [PubMed]
  30. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401. https://doi.org/10.1136/bmj.e1401 doi: 10.1136/bmj.e1401. [DOI] [PMC free article] [PubMed]
  31. Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003;107:811–16. https://doi.org/10.1002/ijc.11474 doi: 10.1002/ijc.11474. [DOI] [PubMed]
  32. Bleeker MC, Berkhof J, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Starink TM, et al. HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. Br J Cancer 2005;92:1388–92. https://doi.org/10.1038/sj.bjc.6602524 doi: 10.1038/sj.bjc.6602524. [DOI] [PMC free article] [PubMed]
  33. Fromm TSK, Gross M, Schädlich L, Kaufmann AM, Albers AE. Laryngeal Papillomatosis: Immunological and Clinical Responses to HPV and Vaccination. 27th International Papillomavirus Conference and Clinical Workshop, Berlin, 17–22 September 2011.
  34. Goldstone SE, Vuocolo S. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. Expert Rev Vaccines 2012;11:395–406. https://doi.org/10.1586/erv.12.20 doi: 10.1586/erv.12.20. [DOI] [PubMed]
  35. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994;75:2075–9. https://doi.org/10.1099/0022-1317-75-8-2075 doi: 10.1099/0022-1317-75-8-2075. [DOI] [PubMed]
  36. Woodhall SC, Jit M, Soldan K, Kinghorn G, Gilson R, Nathan M, et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect 2011;87:458–63. https://doi.org/10.1136/sextrans-2011-050073 doi: 10.1136/sextrans-2011-050073. [DOI] [PMC free article] [PubMed]
  37. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011;343:d5775. https://doi.org/10.1136/bmj.d5775 doi: 10.1136/bmj.d5775. [DOI] [PMC free article] [PubMed]
  38. Murray ML, Meadows J, Doré CJ, Copas AJ, Haddow LJ, Lacey C, et al. Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial). BMC Med Res Methodol 2018;18:125. https://doi.org/10.1186/s12874-018-0581-z doi: 10.1186/s12874-018-0581-z. [DOI] [PMC free article] [PubMed]
  39. Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, et al. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. HIV Med 2016;17:s2–s81. https://doi.org/10.1111/hiv.12424 doi: 10.1111/hiv.12424. [DOI] [PubMed]
  40. Mena G, García-Basteiro AL, Llupià A, Díez C, Costa J, Gatell JM, et al. Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy. Vaccine 2013;31:3668–74. https://doi.org/10.1016/j.vaccine.2013.06.012 doi: 10.1016/j.vaccine.2013.06.012. [DOI] [PubMed]
  41. Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 2013;27:2551–7. https://doi.org/10.1097/QAD.0b013e32836381cc doi: 10.1097/QAD.0b013e32836381cc. [DOI] [PubMed]
  42. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377–99. https://doi.org/10.1002/sim.4067 doi: 10.1002/sim.4067. [DOI] [PubMed]
  43. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health 2015;18:161–72. https://doi.org/10.1016/j.jval.2015.02.001 doi: 10.1016/j.jval.2015.02.001. [DOI] [PubMed]
  44. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE; 2013. [PubMed]
  45. Joint Committee on Vaccination and Immunisation. Code of Practice June 2013. London: Public Health England; 2013.
  46. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2015.
  47. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341–64. https://doi.org/10.1016/S0167-6296(98)00039-3 doi: 10.1016/S0167-6296(98)00039-3. [DOI] [PubMed]
  48. Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care 1998;14:467–71. https://doi.org/10.1017/s0266462300011442 doi: 10.1017/s0266462300011442. [DOI] [PubMed]
  49. NHS Business Services Authority. Drug Tariff 2018. URL: www.nhsbsa.nhs.uk/sites/default/files/2018-10/Drug%20Tariff%20November%202018.pdf (accessed 20 November 2018).
  50. Joint Formulary Committee. British National Formulary. 75 ed. London: BMJ Group and Pharmaceutical Press; 2018.
  51. Organisation for Economic Co-operation and Development (OECD). Consumer Price Indices (CPIs) – Complete Database: Consumer Prices – Annual Inflation, All Items Non-Food Non-Energy. URL: https://stats.oecd.org/Index.aspx?DataSetCode=PRICES_CPI (accessed 20 November 2018).
  52. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36. https://doi.org/10.1007/s11136-011-9903-x doi: 10.1007/s11136-011-9903-x. [DOI] [PMC free article] [PubMed]
  53. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ 2018;27:7–22. https://doi.org/10.1002/hec.3564 doi: 10.1002/hec.3564. [DOI] [PMC free article] [PubMed]
  54. National Institute for Health and Care Excellence. Position Statement on Use of the EQ-5D-5L Value Set for England (Updated October 2019). URL: www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisal-guidance/eq5d5l_nice_position_statement.pdf (accessed 20 November 2018).
  55. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708–15. https://doi.org/10.1016/j.jval.2012.02.008 doi: 10.1016/j.jval.2012.02.008. [DOI] [PubMed]
  56. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96. https://doi.org/10.1002/hec.944 doi: 10.1002/hec.944. [DOI] [PubMed]
  57. Leurent B, Gomes M, Faria R, Morris S, Grieve R, Carpenter JR. Sensitivity analysis for not-at-random missing data in trial-based cost-effectiveness analysis: a tutorial. PharmacoEconomics 2018;36:889–901. https://doi.org/10.1007/s40273-018-0650-5 doi: 10.1007/s40273-018-0650-5. [DOI] [PMC free article] [PubMed]
  58. Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 2008;11:886–97. https://doi.org/10.1111/j.1524-4733.2008.00358.x doi: 10.1111/j.1524-4733.2008.00358.x. [DOI] [PubMed]
  59. Gilson R, Nugent DB, Werner RN, Ballesteros J. 2018 European Guideline for the Management of Anogenital Warts (Draft Version for Consultation). URL: www.iusti.org/regions/Europe/word_docs/2018/IUSTIguidelinesReview2018_08_07.docx (accessed 7 August 2018).
  60. Electronic medicines compendium (emc). Warticon Cream. URL: www.medicines.org.uk/emc/product/1507/smpc (accessed 30 November 2018).
  61. Electronic medicines compendium (emc). Aldara 5% Cream. URL: www.medicines.org.uk/emc/product/823/smpc (accessed 30 November 2018).
  62. Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B, Devlin N. Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets. PharmacoEconomics 2018;36:699–713. https://doi.org/10.1007/s40273-018-0628-3 doi: 10.1007/s40273-018-0628-3. [DOI] [PMC free article] [PubMed]
  63. Hernandez Alava M, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, et al. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Health 2018;21:49–56. https://doi.org/10.1016/j.jval.2017.09.004 doi: 10.1016/j.jval.2017.09.004. [DOI] [PubMed]
  64. Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R, CVT Group. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014;32:5087–97. https://doi.org/10.1016/j.vaccine.2014.06.038 doi: 10.1016/j.vaccine.2014.06.038. [DOI] [PMC free article] [PubMed]
  65. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161–70. https://doi.org/10.1016/S0140-6736(07)60946-5 doi: 10.1016/S0140-6736(07)60946-5. [DOI] [PubMed]
  66. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing . . . presumed at random: cost-analysis of incomplete data. Health Econ 2003;12:377–92. https://doi.org/10.1002/hec.766 doi: 10.1002/hec.766. [DOI] [PubMed]
  67. Devlin N, Brazier J, Pickard AS, Stolk E. 3L, 5L, What the L? A NICE conundrum. PharmacoEconomics 2018;36:637–40. https://doi.org/10.1007/s40273-018-0622-9 doi: 10.1007/s40273-018-0622-9. [DOI] [PMC free article] [PubMed]
  68. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928–43. https://doi.org/10.1056/NEJMoa061760 doi: 10.1056/NEJMoa061760. [DOI] [PubMed]
  69. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915–27. https://doi.org/10.1056/NEJMoa061741 doi: 10.1056/NEJMoa061741. [DOI] [PubMed]
  70. EU Clinical Trials Register. A Randomized, Placebo-controlled, Phase IIIb HPV Vaccination Trial with Gardasil® in Patients with Recurrent Condylomata Acuminata. URL: www.clinicaltrialsregister.eu/ctr-search/trial/2012-004007-13/DE (accessed 7 January 2019).
  71. ClinicalTrials.gov. Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response (CONDYVAC). URL: https://clinicaltrials.gov/ct2/show/ NCT03296397 (accessed 7 January 2019).
  72. Lin JK, Liang YC. Cancer chemoprevention by tea polyphenols. Proc Natl Sci Counc Repub China B 2000;24:1–13. [PubMed]
  73. Kuo CL, Chen TS, Liou SY, Hsieh CC. Immunomodulatory effects of EGCG fraction of green tea extract in innate and adaptive immunity via T regulatory cells in murine model. Immunopharmacol Immunotoxicol 2014;36:364–70. https://doi.org/10.3109/08923973.2014.953637 doi: 10.3109/08923973.2014.953637. [DOI] [PubMed]
  74. Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venereol 2007;21:1404–12. https://doi.org/10.1111/j.1468-3083.2007.02441.x doi: 10.1111/j.1468-3083.2007.02441.x. [DOI] [PubMed]
  75. Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, Thielert C. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 2008;158:1329–38. https://doi.org/10.1111/j.1365-2133.2008.08520.x doi: 10.1111/j.1365-2133.2008.08520.x. [DOI] [PubMed]
  76. Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008;111:1371–9. https://doi.org/10.1097/AOG.0b013e3181719b60 doi: 10.1097/AOG.0b013e3181719b60. [DOI] [PubMed]
  77. Tzellos TG, Sardeli C, Lallas A, Papazisis G, Chourdakis M, Kouvelas D. Efficacy, safety and tolerability of green tea catechins in the treatment of external anogenital warts: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2011;25:345–53. https://doi.org/10.1111/j.1468-3083.2010.03796.x doi: 10.1111/j.1468-3083.2010.03796.x. [DOI] [PubMed]

RESOURCES